| Project/Area Number |
16H06988
|
|---|
| Research Category |
Grant-in-Aid for Research Activity Start-up
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Respiratory surgery
|
|---|
| Research Institution | Okayama University |
|---|
Principal Investigator |
|
|---|
| Research Collaborator |
SATO Hiroki
TOMIDA Shuta
TOYOOKA Shinichi
|
|---|
| Project Period (FY) |
2016-08-26 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Keywords | 非小細胞肺癌 / EGFR / 薬剤耐性 / マイクロRNA / 癌 / トランスレーショナルリサーチ / 薬剤反応性 |
|---|
| Outline of Final Research Achievements |
Patients with EGFR-activating mutations who initially respond to EGFR-tyrosine kinase inhibitors (EGFR-TKIs) eventually acquire drug resistance, which is a critical problem in the treatment of patients with advanced lung cancer. In this study, we clarified the relation between epigenetic alteration and EGFR-TKI resistance. We found that the micro RNA-200 and LIN28B axis, known as an oncogenic stem-cell factor, plays an important role in the cell viability of acquired EGFR-TKI resistance cells.
|
